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Background/aim: In this study, we aimed to evaluate the initial hematological findings analyzed on admission in confirmed COVID-19
patients who were transferred to the intensive care unit (ICU), to predict possible hematological indices.
Materials and methods: Initial neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte
ratio (MLR), red cell distribution width to platelet ratio (RPR), mean platelet volume to platelet ratio, and lymphocyte multiplied by
platelet count (LYM × PLT), of 695 patients with laboratory-confirmed COVID-19 were investigated and comparisons were made
between the mild/moderate and severe groups.
Results: The proportion of COVID-19 cases admitted to the ICU was 3.9%. The median age of patients admitted to the ICU was
significantly higher than those who were not; [68.5 (interquartile range (IQR); 21.5] years vs. 41.0 (IQR; 15.7) years; P < 0.001.
Severe cases had higher NLR (6.6 vs. 2.4; P < 0.001), and MLR (0.40 vs. 0.28; P = 0.004) and lower PLR (180.0 vs. 129.0; P < 0.001)
compared to that of mild or moderate patients. Among all of the parameters, the ROC curve of NLR gave us the best ability to distinguish
serious patients at an early stage (AUC = 0. 819, 95% confidence interval 0.729–0.910; P < 0.001).
Conclusion: These data showed that age, initial NLR, PLR, and LYM × PLT were associated with the severity of COVID-19 disease and
patients’ need for the ICU. Therefore, initial hemogram parameters may be essential to predict the prognosis of COVID-19 patients.
Key words: Intensive care unit, COVID-19, neutrophils, leukocytes, platelets

1. Introduction
In December 2019, a novel coronavirus, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), was
identified in Wuhan, China; and quickly spread around
the World [1]. The World Health Organization named
this infection COVID-19 and announced a pandemic1. In
our country, the first PCR positive COVID-19 case was
detected on March 11th, 20202.
The clinical spectrum of COVID-19 infection can vary
from asymptomatic to severe disease (e.g., acute respiratory

distress syndrome [ARDS], acute cardiac injury, and acute
kidney injury) [1,2]. Up to 32% of all positive patients
require intensive care unit (ICU) admission, and death can
occur [2,3]. Therefore, early identification of patients with
severe disease risk and those that may potentially develop
a life-threatening condition is important.
Increasing evidence supports the role of a dysfunctional
immune response to the airway damage and the progression
of various viral pneumonia, including COVID-19 [4,5].
Hematological indices, such as neutrophil to lymphocyte
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ratio (NLR), platelet to lymphocyte (PLR) ratio, monocyte
to lymphocyte ratio (MLR), lymphocyte count multiplied
by platelet count (LYM × PLT), red cell distribution width
to platelet ratio (RPR), are indicators of the systemic
inflammatory response and have been extensively
investigated in various diseases [6–9]. Abnormal blood
count results were detected in patients with COVID-19
[4,10–12], which are considered to be potential predictors
of the outcomes [13,14].
In this study, we aimed to identify hematological
indices of confirmed COVID-19 patients that were
analyzed on admission and their relationship with the
disease severity, in order for them to be used in predicting
the disease progression.
2. Materials and methods
The study was approved by the ethics committee of SBU
Bursa Yüksek İhtisas Training and Research Hospital (No.
2020/05-02); a pandemic hospital with 1430 beds served as
the setting for the present retrospective cohort study. The
study was conducted in accordance with the principles
outlined in the Declaration of Helsinki.
Combined nasopharyngeal and oropharyngeal swabs
were taken from 1100 patients who met the suspected
case definitions for COVID-19. Real-time quantitative
amplification of SARS CoV RNA was performed with
SARS-CoV-2 (2019-nCoV) RT-qPCR Detection Kit (BioSpeedy®, Bioeksen R&D Technologies, İstanbul, Turkey)
with a thermal cycler device (CFX96TM Real-Time
System, Bio-Rad Laboratories, Singapore) according to
the manufacturer’s instructions. Six-hundred and ninetyfive confirmed SARS-CoV-2 patients admitted to our
hospital between March 27th and April 30th, 2020, were
included in the study. Individuals younger than 18 years
old, those who required aggressive treatment within 24 h
of admission, and those with an absence of initial complete
blood count (CBC) test results were excluded from the
study.
Twenty-seven patients who fulfilled one of the following
criteria; dyspnea and respiratory distress; respiratory rate
> 30/min, PaO2 / FiO2 <300; SPO2 <90 despite 5 L/min
oxygen treatment, PaO2 <70, hypotension (systolic blood
pressure <90 mmHg and/or more than 40 mmHg decrease
and mean arterial pressure <65 mmHg), tachycardia >100/
min, acute kidney injury, development of acute organ
dysfunction, patients with immunosuppression, acute
bleeding diathesis, troponin increase, arrhythmia, lactate
> 2 mmol, capillary return disorder, and cutis marmaratus
were transferred to ICU.
The initial triage protocol of COVID-19 patients
involves drawing blood samples upon admission. CBCs
were analyzed within 1 h after venipuncture using an
automatic blood counter (Mindray BC-5800; Mindray
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Bio-medical Electronics Co. Ltd., Shenzhen, China). Mean
platelet volume divided by platelet count (MPV to PLT)
and lymphocyte multiplied by platelet (LYM × PLT) were
recorded. NLR, PLR, and MLR were calculated by dividing
the number of neutrophils, platelet, and monocyte count
by the lymphocyte count. RDW to platelet ratio (RPR) was
calculated using the formula (RDW ×100 / PLT (109 / L)
[15].
3. Statistical analysis
Statistical analysis was performed using SPSS (Statistical
Package for Social Sciences) for Windows (SPSS Inc,
Chicago, IL), and P values of <0.05 were considered
significant. Descriptive statistics are presented as frequency
distribution and percentage. The Kolmogorov–Smirnov
test was used to identify the distribution of variables.
Statistically significant differences between the variables
were established using the MannWhitney U test. A binary
logistic regression analysis was performed to determine
the influence of age and all other significant factors.
4. Results
The proportion of COVID-19 cases admitted to ICU was
3.9%. Signs and symptoms of severe cases on admission
included self-reported fever (52%), cough (44%), shortness
of breath (52%), sore throat (19%), myalgia/arthralgia
(19%), fatigue (15%), chest pain/discomfort (11%), nasal
symptoms (11%), headache (11%), nausea/vomiting (11%)
and diarrhea (4%).
During the study period, the median age of patients
who were transferred to ICU was significantly higher than
those who were not transferred [68.5 (interquartile range
(IQR); 21.5) years vs. 41.0 (IQR; 15.7) years; P <0.001,
Table 1].
When comparing the initial hemoglobin concentration
[12.9 (4.0) vs. 13.8 (2.3) g/dL; P < 0.001] and lymphocyte
count [12.7% (12.6) vs. 26.6% (15.7)] both values were
found to be lower than that of nonsevere cases (Table 1).
It is observed that severe cases had higher NLR (6.6
vs. 2.4; P < 0.001), and MLR (0.40 vs. 0.28; P = 0.004) and
lower PLR (180.0 vs. 129.0; P < 0.001) compared to mild
or moderate patients (Table 1). The ROC curve of NLR
gave us the best prediction opportunity for distinguishing
patients with severe disease from an earlier stage (AUC
= 0.819, 95% confidence interval 0.729–0.910; P < 0.001,
Table 2).
Potential risk factors, including age, NLR, PLR, LYM
× PLT, and RDW were investigated using binary logistic
regression analysis. Age was found to be the only significant
(b = 0.070, SE = 0.015, P < 0.001) positive predictor for
ICU requirement, with the OR 1.073 (95% CI, 1.042 to
1.104) (Table 3).
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Table 1. Initial laboratory findings of patients with COVID-19.
Group 1 (N = 668)

Group 2 (N = 27)

P value

Age, median (IQR)

41.0 (15.7)

69.0 (21.0)

<0.001

Male/female (%)

47.3/52.7

55.6/44.4

WBC count, ×109/L

6.2 (2.95)

8.3 (5.5)

0.008

Haemoglobin, g/dL

13.8 (2.3)

12.9 (4.0)

0.012

Hct (%)

40.8 (5.9)

38.5 (10.3)

0.017

Platelet count, × 10 /L

217 (74)

192 (90)

0.081

NEU (%)

63.8 (16.7)

82.7 (21.5)

<0.001

LYM (%)

26.6 (15.7)

12.7 (12.6)

<0.001

MONO (%)

7.6 (4.0)

5.9 (5.0)

0.004

EOS (%)

0.7 (1.3)

0.1(0.3)

<0.001

MCV, mm

85.7 (5.8)

84.4 (9.0)

0.321

MCH, pg

29.1 (2.5)

28.2 (4.3)

0.391

MCHC (g/dL)

33.8 (1.2)

33.3 (1.3)

0.003

RDW, %

13.1 (1.2)

13.8 (3.1)

0.007

MPV, fL

9.6 (1.3)

9.7 (1.4)

0.241

CRP, mg/L

6.2 (13)

73 (123)

<0.001

MPV to PLT

0.044 (0.018)

0.053 (0.028)

0.049

NLR

2.4 (2.0)

6.6 (7.8)

<0.001

PLR

129 (70)

180 (156)

<0.001

MLR

0.28 (0.2)

0.40 (0.3)

0.004

LYM × PLT

346.5 (274.9)

169.3 (212.7)

<0.001

RPR

0.062 (0.020)

0.076 (0.028)

0.001

9

3

The patients were divided into two groups: Group 1: Patients not requiring ICU admission;
Group 2: ICU admission required. ICU = intensive care unit; IQR = interquartile range;
RBC = red blood cell; WBC = white blood cell; Hct = hematocrit; NEU = neutrophil; LYM
= lymphocyte; MONO = monocyte; EOS = eosinophils; BASO = basophile; MCV = mean
corpuscular volume; MCH = mean corpuscular haemoglobin, MCHC = mean corpuscular
hemoglobin concentration, RDW = red cell distribution width; MPV = the mean platelet
volume; NLR = neutrophil to lymphocyte ratio; MLR = monocyte to lymphocyte ratio; LYM
× PLT = lymphocyte multiplied by platelet; RPR = red cell distribution width to platelet ratio;
MPV to PLT = mean platelet volume to platelet count ratio. Data are median (IQR) or n (%).

5. Discussion
On admission, the COVID-19 patients who needed to
be taken to the ICU were older than those that did not
require ICU intervention, as reported before [1,2]. In the
ICU-patient group, the initial absolute neutrophil count
was higher, and the lymphocyte count was lower among
patients who were transferred to the ICU compared to mild
cases who were not. This is in accordance with the previous
publications that reported the increase in leukocyte count
and a decrease in lymphocyte count as an indicator for
clinical deterioration in COVID patients [16,17].
Neutrophils are the most important cellular defense
line against infections, which first respond to viral

invasion, and limit the viral replication and spread.
However, neutrophils have also been reported to mediate
deleterious effects on the host during viral infection [18].
The immune response to a viral infection is mainly
based on lymphocytes. It has been assumed that a significant
decrease in lymphocyte count may be due to increased
lymphocyte consumption, destruction of lymphatic tissues,
and cytokine-induced T-cell apoptosis in patients with
COVID-19 [13,19]. Lymphopenia, as a sign of the severe
disease, is not specific to COVID-19. It has also been seen in
other viral causes of pneumonia, such as influenza [20,21].
Notably, we observed that COVID-19 patients who
were transferred to the ICU had lower lymphocyte count
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Table 2. Diagnostic performances of initial hematologic indices
for distinguishing admission to ICU.
Parameter

AUC (95% CI)

NLR

0.819 (0.729–0.910)

LYM × PLT

0.786 (0.706–0.865)

PLR

0.746 (0.629–0.862)

RPR

0.686 (0.584–0.788)

MLR

0.663 (0.560–0.765)

MPV to PLT

0.612 (0.492–0.732)

AUC (95% CI) = area under the receiver operating characteristic
curve (95% confidence interval); NLR = neutrophil to
lymphocyte ratio; LYM = lymphocyte; PLT = platelet; MPV =
mean platelet volume; PLR = platelet to lymphocyte ratio; RPR =
red cell distribution width to platelet count; MLR = monocyte to
lymphocyte ratio; MPV to PLT = mean platelet volume to platelet
count ratio.
Table 3. Binary logistic regression analysis predicting the likelihood of admission to the ICU.
Variable

B

S.E.

OR with 95% Cl

P value

Age

0.070

0.015

1.073 (1.042–1.104)

<0.001

Sex

–0.178

0.479

0.837(0.327–2.141)

0.711

NLR

0.106

0.073

1.112(0.964–1.281)

0.145

LYM × PLT

–0.003

0.002

0.997 (0.994–1.001)

0.209

PLR

0.005

0.003

1.005 (0.999–1.011)

0.086

RPR

2.620

12.244

13.738 (0.00–363400)

0.831

MLR

0.340

0.967

1.405 (0.211–9339)

0.725

MPV to PLT

4.471

12.143

87.422 (0.00–189700)

0.713

OR = odds ratio; Cl = confidence interval; NLR = neutrophil to lymphocyte ratio; LYM =
lymphocyte; PLT = platelet; MPV = mean platelet volume; PLR = platelet to lymphocyte ratio;
RPR = red cell distribution width to platelet; MLR = monocyte to lymphocyte ratio; MPV to PLT
= mean platelet volume to platelet count ratio.

and higher NLR and PLR. In consistency with our study,
Yang et al. suggested NLR ≥3.3 as an indicator with clinical
symptoms to change disease status from mild to severe disease
[22]. NLR is reported to be used as an early indicator for the
severe disease, similar to previous findings from a different
patient population [22,23].
In the current study, the median PLR of severe COVID
patients was higher compared to that of nonsevere cases.
The PLR, which reflects both aggregation and inflammation
control, is a better marker for the decision of patients for
transfer to the ICU than platelet or lymphocyte count alone.
Changes in platelet count and activity are closely related to
various diseases [24]. It has been shown in several studies that
low platelet count is directly related to the severity of the disease
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in COVID-19 patients [12,25]. Platelets not only contribute
to hemostasis but also participate in the inflammation and
host defense. Decreased platelet production and increased
consumption due to diffuse alveolar damage are thought to
cause thrombocytopenia in COVID-19 patients [26,27].
In accordance with previous studies, the hemoglobin
level was found to be lower in COVID patients who needed
to be taken to the ICU when compared to that of milder
COVID patients [28,29]. RDW is a measure of the change in
erythrocyte volume and has been reported to be a predictor of
mortality in some conditions, including infections [30]. The
higher RDW is associated to increased inflammation markers
which have been tightly correlated with the critical disease
[31,32].
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6. Conclusion
According to the results of this study, the variables,
including the age of the patients, NLR, PLR, and LYM
× PLT, are related to the severity of COVID-19 disease
and may contribute to decision making for transferring
patients to the ICU on admission. Therefore, initial
CBC parameters should be monitored for predicting the
prognosis of COVID-19 patients.
Limitation: This study was a retrospective, singlecenter study. Prospective and multicenter clinical studies

might be required to avoid a certain degree of deviation
and to support the findings.
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